Executive search firm Toft Group has placed Mr. Kevin Boyle, Sr. as Chief Financial Officer at Cell Medica, Inc., in Houston, TX. With over 20 years of financial and capital markets experience, Kevin joins the senior executive team as the company prepares for ground-breaking clinical trials to investigate cancer treatments utilizing Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.
Kevin has held senior finance roles at both NASDAQ-listed and private equity backed companies. He is an accomplished capital markets professional with strong banking relationships cultivated by raising over $2.0 billion in equity and debt capital. Kevin received a law degree from the University of Pennsylvania and a BS in Industrial Management & Economics from Carnegie Mellon University.
About Cell Medica
Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with our strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Our lead product is CMD-003 is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. We are working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR- modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, we are collaborating with University College London to develop the Dominant TCR technology platform.
Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.